


CLAIMS

1. A compound of Formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

--- is a single bond or a double bond;

R^1 and R^2 are independently H or halogen;

R^3 is independently selected from: halogen, phenyl, and a 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR^a , O, and $S(O)_p$; wherein said phenyl and heteroaryl are substituted with 0-3 R^{3A} ;

each R^{3A} is independently selected from: halogen, CN, $-(O)_m-(C_1-C_6 \text{ alkyl})$ substituted with 0-1 R^{3B} , C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, R^{3C} , $-OR^{3C}$, $-C(=O)R^{3D}$, $NR^{3E}R^{3F}$, $-C(=O)NR^{3E}R^{3F}$, $-NHC(=O)R^{3D}$, $-S(=O)_2R^{3D}$, $-S(=O)_2NR^{3E}R^{3F}$, $-NHS(=O)_2(C_1-C_4 \text{ alkyl})$, and $-CR^{3C}R^{3E}R^{3G}$;

R^{3B} is independently selected from: OH, NR^eR^f , C_1-C_4 alkoxy, $-C(=O)NR^eR^f$, $-S(=O)_2(C_1-C_4 \text{ alkyl})$, $-NHC(=O)(C_1-C_4 \text{ alkyl})$, and a 5- to 6-membered heterocycloalkyl comprising carbon atoms and 1-2 heteroatoms selected from N, NR^a , O, and $S(O)_p$; wherein said heterocycloalkyl is substituted with 0-2 R^c ;

each R^{3C} is independently selected from: C_3-C_6 cycloalkyl, phenyl, and a 4- to 7-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NR^a , O, and $S(O)_p$; wherein each moiety is substituted with 0-2 R^c ;

each R^{3D} is independently selected from: C_1-C_4 alkyl and R^{3C} ;

R^{3E} and R^{3G} are, at each occurrence, independently selected from: H and C_1-C_4 alkyl;

each R^{3F} is independently selected from: H and C₁-C₄ alkyl substituted with 0-1 R^d ;

R^4 is independently selected from: H, halogen and C₁-C₄ alkyl;

R^5 is independently selected from OH and C₁-C₄ alkyl;

each R^a is independently selected from: H, $\rightarrow O$, C₁-C₄ alkyl substituted with 0-1 R^b , -C(=O)H, -C(=O)(C₁-C₄ alkyl), -CO₂(C₁-C₄ alkyl), C₃-C₆ cycloalkyl, and benzyl;

R^b is independently selected from: halogen, OH and C₁-C₄ alkoxy;

each R^c is independently selected from: =O, halogen, OH, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, and C₁-C₄ haloalkoxy;

R^d is independently selected from: OH and NR^eR^f ;


R^e and R^f are, at each occurrence, independently selected from: H and C₁-C₄ alkyl;

each p is independently selected from 0, 1 and 2; and

m and n are, at each occurrence, independently selected from 0 and 1.

2. A compound or a pharmaceutically acceptable salt thereof, according to claim 1, wherein:

each R^{3A} is independently selected from: halogen, CN, $-(O)_m$ -(C₁-C₄ alkyl substituted with 0-1 R^{3B}), C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, R^{3C} , -C(=O) R^{3D} , $NR^{3E}R^{3F}$, -C(=O) $NR^{3E}R^{3F}$, -S(=O)₂ R^{3D} , -S(=O)₂NHR^{3F}, -NHS(=O)₂(C₁-C₄ alkyl),



-O-C₃-C₆ cycloalkyl, and ;

R^a is independently selected from: H, $\rightarrow O$, C₁-C₄ alkyl substituted with 0-1 R^b , -C(=O)H, -C(=O)(C₁-C₄ alkyl), -CO₂(C₁-C₄ alkyl), and C₃-C₆ cycloalkyl;

R^4 is H;

m is independently selected from 0 and 1; and

n is 0.

3. A compound or a pharmaceutically acceptable salt thereof, according to claim 2, wherein:

R^1 is independently H or F;


R^2 is H; and

R^3 is independently selected from: phenyl, and a 6-membered heteroaryl comprising carbon atoms and 1-2 heteroatoms selected from N and NR^a ; wherein said phenyl and heteroaryl are substituted with 0-3 R^{3A} .

4. A compound or a pharmaceutically acceptable salt thereof, according to claim 3, wherein:

R^3 is independently selected from: phenyl, pyridyl, pyrimidyl, pyridazinyl and pyrazinyl; wherein each moiety is substituted with 0-3 R^{3A} .


5. A compound or a pharmaceutically acceptable salt thereof, according to claim 4, wherein:







R^3 is independently selected from:

6. A compound or a pharmaceutically acceptable salt thereof, according to claim 4, wherein:

R^3 is independently selected from:





each R^{3A} is independently selected from: halogen, CN, $-(O)_m-(C_1-C_4 \text{ alkyl})$ substituted with 0-1 R^{3B} , C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, $-C(=O)NH_2$, $-C(=O)NH(C_1-C_4 \text{ alkyl})$, $-C(=O)N(C_1-C_4 \text{ alkyl})_2$, $-C(=O)N(C_1-C_4 \text{ alkyl})(CH_2)_2N(C_1-C_4 \text{ alkyl})_2$, $-CH_2NHC(=O)(C_1-C_4 \text{ alkyl})$, $-S(=O)_2R^{3D}$, $-S(=O)_2NH(C_1-C_4 \text{ alkyl})$ substituted with 0-1 OH, $-NHS(=O)_2(C_1-C_4 \text{ alkyl})$, NH_2 , $-NH(C_1-C_4 \text{ alkyl})$, $-N(C_1-C_4 \text{ alkyl})_2$, C_3-C_6



and ;


R^{3B} is independently selected from: OH, NH_2 , $NH(C_1-C_4 \text{ alkyl})$, $N(C_1-C_4 \text{ alkyl})_2$,



R^{3D} is independently selected from: C_1-C_4 alkyl and 1H-piperidin-4-yl; and

each R^a is independently selected from: H, C_1-C_4 alkyl, $-C(=O)H$, $-C(=O)(C_1-C_4 \text{ alkyl})$, and $-CO_2(C_1-C_4 \text{ alkyl})$.





7. A compound or a pharmaceutically acceptable salt thereof, according to claim 6, wherein:





R^3 is independently selected from:

each R^{3A} is independently selected from: halogen, CN, $-(O)_m-(C_1-C_4 \text{ alkyl})$ substituted with 0-1 R^{3B} , C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, $-C(=O)NH_2$, $-C(=O)NH(C_1-C_4 \text{ alkyl})$, $-C(=O)N(C_1-C_4 \text{ alkyl})_2$, $-C(=O)N(C_1-C_4 \text{ alkyl})(CH_2)_2N(C_1-C_4 \text{ alkyl})_2$, $-CH_2NHC(=O)(C_1-C_4 \text{ alkyl})$, $-S(=O)_2(C_1-C_4 \text{ alkyl})$, NH_2 , $NH(C_1-C_4 \text{ alkyl})$, $N(C_1-C_4$

$alkyl)_2$, C_3-C_6 cycloalkyl,



R^{3B} is independently selected from: OH, $N(C_1-C_4 \text{ alkyl})_2$, C_1-C_4 alkoxy,




; and


each R^a is independently selected from: H, C_1-C_4 alkyl, $-C(=O)H$, $-C(=O)(C_1-C_4 \text{ alkyl})$, and $-CO_2(C_1-C_4 \text{ alkyl})$.

8. A compound or a pharmaceutically acceptable salt thereof, according to claim 7, wherein:

each R^{3A} is independently selected from: F, Cl, CH_3 , $-CH_2OH$, CH_2F , CHF_2 , CF_3 , CN, $-OCH_3$, $-OCH_2CH_3$, $-OCH(CH_3)_2$, $-OCHF_2$, $-C(=O)N(CH_3)_2$, $-CH_2NHC(=O)CH_3$,



9. A compound or a pharmaceutically acceptable salt thereof, according to claim 1, wherein said compound is of Formula (IA-1):



or a pharmaceutically acceptable salt thereof, wherein:

R^1 is independently H or F; and

R^{3A} is independently selected from: F, CH_3 , $-CH_2OH$, CH_2F , CHF_2 , CF_3 , and $-OCH_3$.

10. A compound or a pharmaceutically acceptable salt thereof, according to claim 9, wherein:

R^1 is F.

11. A compound according to claim 1, wherein:

R^1 is independently H or F;


R^2 is H;

R^3 is independently a 5-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR^a , O, and $S(O)_p$; wherein said heteroaryl is substituted with 0-3 R^{3A} ; and

R^a is independently selected from: H, C_1 - C_4 alkyl substituted with 0-1 R^b , $-C(=O)H$, $-C(=O)(C_1$ - C_4 alkyl), $-CO_2(C_1$ - C_4 alkyl), C_3 - C_6 cycloalkyl, and benzyl.


12. A compound or a pharmaceutically acceptable salt thereof, according to claim 11, wherein:

R^3 is independently selected from:



13. A compound or a pharmaceutically acceptable salt thereof, according to claim 1, wherein said compound is selected from Examples 1 to 245.

14. A compound according to claim 1, wherein said compound is selected from:



or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition, comprising one or more pharmaceutically acceptable carriers and a compound or a pharmaceutically acceptable salt thereof, according to claim 1.

16. The pharmaceutical composition of claim 15 further comprising at least one additional therapeutic agent.
17. The pharmaceutical composition of claim 16 where said at least one additional therapeutic agent is selected from other anti-cancer agents, immunomodulators, anti-allergic agents, anti-emetics, pain relievers, cytoprotective agents, and combinations thereof.
18. A therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, according to claim 1 for use in the treatment of a disease or disorder mediated by EED and/or PRC2; wherein said disease or disorder is selected from diffuse large B cell lymphoma, follicular lymphoma, other lymphomas, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast carcinoma, bile duct and gallbladder cancers, bladder carcinoma, brain tumors including neuroblastoma, schwannoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancers, parathyroid tumors, uterine tumors, and soft tissue sarcomas.
19. Use of a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, according to claim 1 in the manufacture of a medicament for the treatment of a disease or disorder mediated by EED and/or PRC2; wherein said disease or disorder is selected from diffuse large B cell lymphoma, follicular lymphoma, other lymphomas, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast carcinoma, bile duct and gallbladder cancers, bladder carcinoma, brain tumors including neuroblastoma, schwannoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, pancreatic cancer, renal cell

carcinoma, rectal cancer, thyroid cancers, parathyroid tumors, uterine tumors, and soft tissue sarcomas.

20. A compound according to claim 1, wherein said compound is 8-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof.

21. A compound according to claim 1, wherein said compound is *N*-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof.